Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMUJ0W7)

Drug Name
CP-724714 Drug Info
Synonyms
CP 724714; CP-724,714; CP724,714, CP-724,714; 2-Methoxy-N-(3-(4-((3-methyl-4-((6-methyl-3-pyridinyl)oxy)phenyl)amino)-6-quinazolinyl)-2-propenyl)acetamide; 2-Methoxy-N-[(2E)-3-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-6-quinazolinyl]-2-propen-1-yl]acetamide
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
9874913
ChEBI ID
CHEMBL483321
CAS Number
CAS 845680-17-3
TTD Drug ID
D0CN9Q
VARIDT Drug ID
DR01390

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.25 0.00e+0 34/36 (94.44%) MCM5;PCNA;FEN1;...
Drug metabolism 2.08 0.00e+0 78/151 (51.66%) GSTA1;ADH1B;CYP2A6;...
One carbon pool by folate 1.86 2.83e-3 15/20 (75%) TYMS;DHFR;MTHFD1;...
Mismatch repair 1.85 2.12e-3 22/23 (95.65%) PCNA;RFC2;MSH6;...
Nitrogen metabolism 1.84 6.78e-3 16/17 (94.12%) CA12;CA2;CPS1;...
Pyrimidine metabolism 1.77 1.70e-2 40/56 (71.43%) TYMS;CTPS1;CANT1;...
Retinol metabolism 1.77 1.45e-2 41/68 (60.29%) ADH1B;CYP2A6;UGT2B4;...
Non-homologous end-joining 1.74 2.54e-2 11/13 (84.62%) FEN1;XRCC5;RAD50;...
Central carbon metabolism in cancer 1.71 3.77e-2 67/70 (95.71%) SIRT3;HK2;PFKP;...
Citrate cycle (TCA cycle) 1.68 4.92e-2 30/30 (100%) DLD;SDHA;FH;...
Natural killer cell mediated cytotoxicity -1.74 3.65e-2 99/131 (75.57%) IFNG;SHC3;ZAP70;...
Lysosome -1.75 3.88e-2 115/128 (89.84%) ACP5;IDS;CLTB;...
Phagosome -1.75 4.15e-2 118/152 (77.63%) ATP6V0E2;SEC61G;ATP6V1A;...
Graft-versus-host disease -1.75 4.23e-2 32/42 (76.19%) HLA-DMB;HLA-DRA;GZMB;...
Vibrio cholerae infection -1.77 3.60e-2 44/50 (88%) TJP2;ADCY9;SLC12A2;...
Mitophagy -1.81 2.63e-2 56/68 (82.35%) BNIP3;EIF2AK3;BECN1;...
Rheumatoid arthritis -1.83 2.31e-2 78/93 (83.87%) IL23A;ATP6V0A1;ATP6V0E2;...
Type I diabetes mellitus -1.91 6.92e-3 38/43 (88.37%) GAD2;HLA-DMB;HLA-DRA;...
Viral myocarditis -2.04 0.00e+0 53/60 (88.33%) ITGAL;HLA-DMB;HLA-DRA;...
Allograft rejection -2.08 0.00e+0 32/38 (84.21%) HLA-DMB;HLA-DRA;GZMB;...
Other glycan degradation -2.19 0.00e+0 13/18 (72.22%) AGA;ENGASE;HEXA;...
Mineral absorption -2.36 0.00e+0 48/60 (80%) CYBRD1;HEPH;VDR;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.04uM - 10uM 3H, 6H, 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H